Vertex Pharmaceuticals (VRTX) Finished Goods (2011 - 2012)
Vertex Pharmaceuticals' (VRTX) quarterly Finished Goods came in at $23.3 million in Q3 2012, up 94.18% year-on-year from $12.0 million in Q4 2011, and down 0.81% quarter-over-quarter from $23.5 million in Q2 2012.
Vertex Pharmaceuticals (VRTX) Finished Goods (2011 - 2012) Analysis & Trends
Vertex Pharmaceuticals' Finished Goods history runs 2 years deep, the most recent figure standing at $23.3 million for Q3 2012.
- On a quarterly basis, Finished Goods rose 94.18% year-over-year to $23.3 million in Q3 2012; TTM through Sep 2012 was $23.3 million, a 94.18% increase from a year earlier, with the FY2011 full-year figure at $33.2 million, changed N/A from the prior year.
- Finished Goods slipped to $23.3 million in Q3 2012 per VRTX's latest filing, from $23.5 million in the prior quarter.
- Across five years, Finished Goods topped out at $33.2 million in Q4 2011 and bottomed at $12.0 million in Q3 2011.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - |
| 10 | Alnylam Pharmaceuticals | 36.08 Bn | 33.07 Bn | 959.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2012 | 23.32 Mn |
| Jun 30, 2012 | 23.51 Mn |
| Mar 31, 2012 | 26.35 Mn |
| Dec 31, 2011 | 33.21 Mn |
| Sep 30, 2011 | 12.01 Mn |